Effects of oxaliplatin and 5-fluorouracil on the healing of colon anastomoses.
OBJECTIVE
Oxaliplatin (OX) and 5-fluorouracil (5-FU) are the most widely used chemotherapeutic agents in the adjuvant treatment of colon cancer. Although the early initiation of adjuvant chemotherapy can improve the outcome of surgery, it carries potentially fatal risks. This experimental study investigates the effects of 5-FU and OX on colon anastomoses.


METHODS
We used 60 rats, divided into six groups. After being subjected to bowel resection and anastomosis, the rats were given 5-FU on days 1-3, or OX 130 mg/m(2) on days 1 or 5, or 5% dextrose as a control. The bursting pressures and hydroxyproline content of the anastomoses were measured, and complications and adhesions were recorded.


RESULTS
There were no major complications in the treatment groups. The bursting pressures of the 5-FU group were significantly lower than those of the control and OX groups. The bursting pressures of the OX groups were not significantly different from those of the control groups. The hydroxyproline levels of the rats treated with OX on day 1 were significantly lower than those of the rats treated with OX on day 5 and the 5-FU groups.


CONCLUSIONS
Oxaliplatin and 5-FU did not compromise wound healing of the colon significantly. Our results indicate that OX is less detrimental to the healing of colonic anastomoses, when administered on days 1 and 5 after resection, than 5-FU.
Ersoy
Eren
E
Department of General Surgery, Ankara Atatürk Research and Education Hospital, Acar Beytepe Evleri No: 154/27, Beytepe, Ankara, Turkey.
Akbulut
Hakan
H
Moray
Gökhan
G
D000714:Anastomosis, Surgical; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000601:surgery; D004195:Disease Models, Animal; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects*; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077150:Oxaliplatin; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013529:Surgical Wound Dehiscence / Q000139:chemically induced; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects; D014945:Wound Healing / Q000187:drug effects*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005472:Fluorouracil